Compare Lowe`s Companies Inc (LOW) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Mesoblast Limited — how do they compare? Lowe`s Companies Inc trades at $186 (market cap $105.96B), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Lowe`s Companies Inc is far larger — about 60.5× Mesoblast Limited's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Mesoblast Limited for 15 Days on average.
| LOW | MESO | |
|---|---|---|
Market Cap | $105.96B | $1.75B |
Volume | 4,039,547 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $20.96 |
52-Week Low | $179.50 | $13.19 |
Typical Hold Time | 98 Days | 15 Days |
Enterprise Value | $144.81B | $1.83B |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.85, up 4.03% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with 7.35% net margins and reasonable valuation at 15.96 P/E. Recent drone delivery innovation with DoorDash and Alphabet demonstrates operational adaptation amid challenging home improvement market conditions.
Outlook remains cautious with housing market headwinds, though analyst consensus targets $244.09 (29% upside). Key risks include interest rate sensitivity and competitive pressure from Home Depot. The company's Dividend King status and consistent cash flow generation provide stability for long-term investors.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
